TNNC1 and heart failure: At present, Ca2+ metabolism is already an established target in heart failure therapy in humans with the agent levosimendan which is a Ca2+-sensitizer acting through binding to the cardiac troponin C molecule – a modulator of force of contraction in the cardiomyocyte37.